Table 1.
The list of the ongoing clinical trials for NF2 syndrome.
| NCT 1 (or KCT 2) Numbers | Treatment (Inhibitors) |
Stage (Site) |
Estimated Enrollment (Persons) | Study Type | Study Start (Year-Month) /Primary Completion (Estimated) /Study Completion (Estimated) |
|---|---|---|---|---|---|
| NCT03095248 | Selumetinib (MEK inhibitor) |
Phase II (USA) |
34 | Interventional | 2017-05 /2024-06 /2025-06 |
| NCT05130866 | REC-2282 (HDAC inhibitor) |
Phase II/III (USA) |
92 | Interventional | 2022-06 /2027-01 /2027-07 |
| NCT04283669 | Crizotinib (ALK and ROS1 inhibitor) |
Phase II (USA) |
19 | Interventional | 2020-02 /2025-08 /2025-12 |
| NCT04374305 | Brigatinib (ALK and EGFR inhibitor) Neratinib (HER tyrosine kinase 3 inhibitor) |
Phase II (USA) |
100 | Interventional | 2020-06 /2029-12 /2030-12 |
| KCT0009520 | PRG-N-01 (TβR1/RKIP PPI inhibitors) |
Phase I/II (Republic of Korea) |
I: 36 II: 30 |
Interventional | 2024-05 /2028-06 /2028-12 |
1 NCT: National Clinical Trial. 2 KCT: Korea Clinical Trial. 3 HER tyrosine kinase: pan-human epidermal growth factor receptor tyrosine kinase.